ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1481

Dementia in Adults with Systemic Lupus Erythematosus 65 Years of Age and Above: A National Administrative Claims Data Analysis

Sarah Lieber1, Musarrat Nahid2, Iris Navarro-Millan2, Mangala Rajan2, Sebastian Sattui3, Robyn Lipschultz1, M. Carrington Reid2 and Lisa Mandl1, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine, New York, NY, 3University of Pittsburgh, Pittsburgh, PA

Meeting: ACR Convergence 2022

Keywords: Aging, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Systemic lupus erythematosus (SLE) has been associated with increased risk of dementia relative to age-matched comparators without systemic rheumatic disease (SRD) in non-US-based samples including primarily young and mid-aged adults [1-4]. Dementia prevalence in aging adults with SLE in the US population is not well understood. Using a national administrative claims dataset, we sought to ascertain dementia prevalence in adults with SLE ≥65 years of age compared to age- and gender-matched non-SRD comparators and differences in clinical characteristics between these groups.

Methods: We identified patients with SLE ≥65 years of age enrolled in a 5% random sample of Centers for Medicare and Medicaid Services Medicare in 2006 based on ≥2 International Classification of Diseases, Ninth Revision (ICD-9) codes (710.0) from hospital discharge diagnoses or physician visit claims, with each claim separated by ≥30 days. Age- and gender-matched comparators with osteoarthritis (≥1 ICD-9 code of 715), but no SRD were identified in a 4:1 ratio. Dementia prevalence was determined using a previously validated algorithm [5]: ≥1 inpatient dementia claim (ICD-9 code of 290.xx, 294.1x, or 331.xx), ≥2 outpatient claims, or prescription of a dementia-specific medication (rivastigmine, galantamine, memantine, donepezil, or tacrine). Sociodemographic features, comorbid conditions, and medications were assessed for patients with SLE and non-SRD comparators.

Results: In this cross-sectional study, we identified 1338 patients with SLE and 5352 matched comparators without SRD. Participants were predominantly female (88.1%), with median age of 73.4 years. Patients with SLE had greater comorbidity burden, higher prevalence of cardiovascular disease (CVD) despite lower prevalence of traditional CVD risk factors (diabetes mellitus, hyperlipidemia), and higher proportion of hydroxychloroquine, glucocorticoid, and immunosuppressive medication use than non-SRD comparators (all p< 0.01). Dementia prevalence did not differ significantly between patients with SLE (4.8%) and non-SRD comparators (5.8%).

Conclusion: In contrast to prior studies of non-US-based samples including primarily young and mid-aged adults, dementia prevalence was similar between older adults with SLE and non-SRD comparators in this US-based sample. Further study is underway to examine secular trends in dementia prevalence among aging US adults with and without SLE.

References:
1. Lin et al. Arthritis Care Res 2016;68:1774-9.
2. Wotton and Goldacre. J Epidemiol Community Health 2017;71:576-83.
3. Gendelman et al. Int J Geriatr Psychiatry 2018;33:531-6.
4. Zhao et al. Dement Neuropsychol 2018;12:143-51.
5. Sattui et al. Semin Arthritis Rheum 2021;51:292-8.

Supporting image 1

Table 1. Prevalence of dementia and sociodemographic and clinical characteristics in patients with systemic lupus erythematosus (SLE) and non-systemic rheumatic disease (SRD) comparators


Disclosures: S. Lieber, None; M. Nahid, None; I. Navarro-Millan, Sweden Orphan Biovitrum (SOBI); M. Rajan, None; S. Sattui, AstraZeneca; R. Lipschultz, None; M. Reid, None; L. Mandl, Pfizer.

To cite this abstract in AMA style:

Lieber S, Nahid M, Navarro-Millan I, Rajan M, Sattui S, Lipschultz R, Reid M, Mandl L. Dementia in Adults with Systemic Lupus Erythematosus 65 Years of Age and Above: A National Administrative Claims Data Analysis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/dementia-in-adults-with-systemic-lupus-erythematosus-65-years-of-age-and-above-a-national-administrative-claims-data-analysis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dementia-in-adults-with-systemic-lupus-erythematosus-65-years-of-age-and-above-a-national-administrative-claims-data-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology